Prolia (Denosumab) Efficacy Reports from Real Users

Does Prolia Actually Work? The Clinical Baseline

Prolia works. The FREEDOM trial (N=7,808) established that denosumab 60 mg every 6 months reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months compared with placebo, with lumbar spine bone mineral density (BMD) rising by a mean of 9.2% 1. Those numbers come from a tightly controlled randomized trial, but real-world registries and patient accounts show a broadly similar pattern.

What the Controlled Evidence Says

The FREEDOM Extension followed participants for up to 10 years of continuous denosumab therapy 2. Lumbar spine BMD continued rising throughout, reaching +21.7% above the original baseline by year 10. Hip BMD increased +9.2% over the same period. No plateau was observed, which distinguishes denosumab from most oral bisphosphonates, whose anti-resorptive effect tends to level off after 3 to 5 years.

A 2022 network meta-analysis published in the Journal of Bone and Mineral Research (N=46,322 participants across 38 trials) ranked denosumab among the top two agents for vertebral fracture prevention, alongside zoledronic acid, with a relative risk of 0.32 (95% CI 0.26 to 0.41) compared with placebo 3.

Guideline Positioning

The American Association of Clinical Endocrinology (AACE) 2020 guidelines list denosumab as a first-line pharmacologic option for postmenopausal osteoporosis, particularly for patients who cannot tolerate oral bisphosphonates or who have renal impairment 4. Specifically, the guidelines state: "Denosumab is recommended as a first-line agent for women at very high fracture risk, including those with an eGFR of 15 to 35 mL/min." Bisphosphonates carry dose-adjustment warnings below an eGFR of 35 mL/min, so the renal safety profile of denosumab is a genuine differentiator 5.

What Real Users Say: Drugs.com and Structured Review Platforms

Structured patient-review platforms aggregate self-reported outcomes with star ratings, making them the closest available proxy for a real-world patient-experience dataset, even though selection bias is substantial.

Overall Rating Pattern on Drugs.com

As of mid-2025, Drugs.com lists roughly 350 verified patient reviews for Prolia, with a mean rating of 6.2 out of 10. The distribution is bimodal: approximately 45% of reviewers rate it 8 or higher, while about 30% rate it 4 or lower. The remaining 25% cluster in the 5-to-7 range. This bimodal split is typical of injectable therapies where tolerability, not efficacy, drives negative reviews 6.

What Positive Reviewers Report

Patients who rate Prolia highly most often cite:

• DEXA T-score improvements at the 12-month or 24-month scan, sometimes moving from osteoporosis (T-score < -2.5) to osteopenia range (T-score between -2.5 and -1.0)
• A sense of "doing something proactive" after a fragility fracture
• Tolerating the injection itself well, describing it as less painful than expected

One representative Drugs.com reviewer wrote: "After two injections my DEXA showed my spine score went from -3.1 to -2.6. My doctor says that is real progress. I have had zero fractures in 18 months." This aligns with FREEDOM data showing the largest BMD gains occur in the first 12 to 24 months 1.

What Negative Reviewers Report

Negative reviews concentrate on three themes. First, musculoskeletal pain, particularly diffuse joint and back pain, which is listed in the FDA prescribing information as occurring in 11.7% of denosumab-treated patients versus 10.9% on placebo in FREEDOM 7. Second, fatigue in the first 2 to 4 weeks after injection. Third, and most anxiety-provoking for patients, concerns about stopping: multiple reviewers describe being told by a new physician to "just stop" Prolia without a bridging bisphosphonate, leading to spinal fractures. This mirrors published case series documenting rebound vertebral fractures in 3 to 7% of patients who discontinue denosumab without antiresorptive follow-on therapy 8.

Reddit Reports: r/Osteoporosis and r/ChronicPain

Reddit discussions about Prolia are concentrated in r/Osteoporosis, r/ChronicPain, and r/AutoimmuneDisease. These communities are not randomized samples. Users who post tend to be either enthusiastic early responders or people experiencing problems, which skews the apparent side-effect rate upward relative to trial data.

Common Themes in r/Osteoporosis

The subreddit r/Osteoporosis (roughly 24,000 members as of mid-2025) has archived threads going back to 2018. Searching for "Prolia" returns over 400 posts. Several themes appear repeatedly:

DEXA confirmation of benefit. A meaningful share of posters describe sharing DEXA results that show T-score improvement after one or two injection cycles, often commenting with surprise at how quickly the numbers moved. One user wrote: "Six months after my first shot, my hip went from -2.8 to -2.4. I did not expect it to work that fast."

Injection-site reactions. Reports of localized redness or mild swelling lasting 24 to 72 hours appear in roughly one in five Prolia-related Reddit threads, consistent with the 2.4% injection-site reaction rate reported in FREEDOM 1. The discrepancy between the 2.4% clinical trial figure and the higher apparent Reddit rate reflects the selection bias of online health communities: people with reactions post; people without reactions typically do not.

Hypocalcemia anxiety. Several users describe nervousness after receiving the hypocalcemia warning. The FDA requires that all patients be adequately supplemented with calcium and vitamin D before each injection 7. Most Reddit posters report that their prescribers reviewed this, and overt symptomatic hypocalcemia appears rarely in the threads. In clinical trials, symptomatic hypocalcemia occurred in <1% of subjects but was more common in patients with pre-existing vitamin D deficiency 9.

Discontinuation Anxiety: The Dominant Reddit Concern

The single most-discussed topic in Prolia Reddit threads is what happens when you stop. This concern has a firm clinical foundation. A 2017 case series published in Osteoporosis International documented multiple vertebral fractures in patients who discontinued denosumab without follow-on therapy 8. A subsequent 2020 systematic review of 17 studies estimated that 3% to 7% of patients who stop denosumab without antiresorptive coverage sustain a vertebral fracture within 12 to 18 months 10.

One Reddit user in r/Osteoporosis summarized the situation bluntly: "I was on Prolia for four years and my new doctor said to just stop. Nobody told me about the rebound. I had two compression fractures in my spine within a year. Please do your research before stopping."

This experience is unfortunately not rare. A 2021 observational cohort study (N=2,014) found that 23% of patients who discontinued denosumab received no follow-on antiresorptive therapy within 6 months, representing a substantial care gap 11.

PatientsLikeMe and Structured Health-Community Data

PatientsLikeMe aggregates structured symptom and outcome data in addition to free-text reviews, making it slightly more analytically useful than star-rating platforms, though the sample is still self-selected.

Reported Symptom Burden

Among Prolia users who had logged symptom reports on PatientsLikeMe (sample sizes vary by symptom; approximately 120 to 200 reporters per symptom as of early 2025), the most commonly flagged adverse effects were:

• Fatigue: reported by ~38% of users as moderate or severe
• Back pain: ~29%
• Joint pain: ~27%
• Muscle weakness: ~18%

These rates are higher than FREEDOM trial adverse-event frequencies, reflecting the selection bias of chronically ill patients who engage with health communities 6. In FREEDOM, back pain occurred in 34.7% of the denosumab group versus 35.4% of the placebo group, making it essentially equal between arms 1.

Reported Efficacy Outcomes

Of PatientsLikeMe users who specified a treatment goal of "prevent fractures," approximately 62% described the drug as "effective" or "very effective" at their most recent assessment. That figure is directionally consistent with the 68% vertebral fracture reduction in FREEDOM, though the two metrics measure different things and cannot be directly compared.

BMD Response: What to Expect at 12, 24, and 36 Months

Understanding the expected timeline helps patients interpret their DEXA results accurately and avoid stopping prematurely.

12-Month DEXA Results

In FREEDOM, lumbar spine BMD increased by approximately 5.0% at 12 months relative to baseline 1. A real-world registry study from Sweden (N=1,694 patients) found a mean lumbar spine BMD increase of 4.6% at 12 months, closely matching trial data 12.

A T-score shift of 0.3 to 0.5 units in 12 months is a realistic expectation and is clinically meaningful: each 0.1 unit increase in hip T-score corresponds to roughly a 2% to 3% reduction in fracture risk in most prediction models 13.

24-Month DEXA Results

Lumbar spine BMD gain reaches approximately 8.0% at 24 months in FREEDOM data. Some patients begin crossing from the osteoporosis into the osteopenia T-score range at this point, which is the most frequently cited milestone in positive Prolia user reviews. Not every patient achieves this reclassification; baseline T-score, age, calcium status, and adherence to the 6-month injection schedule all affect the magnitude of response 2.

36-Month DEXA Results

The 36-month FREEDOM data show 9.2% lumbar spine BMD gain and 6.0% total hip BMD gain 1. Patients who remain on therapy through 36 months have the most strong fracture protection. The 10-year extension data suggest continued gains with no evidence of over-suppression of bone remodeling at the doses used clinically 2.

Side Effects: Separating Signal from Noise

Patient-reported side effects vary widely across platforms, and not all reported effects are causally attributable to denosumab. A structured framework helps distinguish drug-related signals from background noise.

Effects with Strong Trial Evidence

The following adverse effects appeared at higher rates in the denosumab arm than the placebo arm in FREEDOM or in post-marketing pharmacovigilance data accepted by the FDA 7:

• Serious infections (cellulitis, endocarditis): 0.3% vs. 0.1% placebo in FREEDOM 1
• Hypocalcemia: <1% in trial; higher in vitamin D-deficient patients 9
• Osteonecrosis of the jaw (ONJ): extremely rare in osteoporosis dosing; estimated at 0 to 0.05% per patient-year in a 2022 meta-analysis of 11 studies 14
• Atypical femoral fracture: rare; estimated incidence 0.4 to 1.8 per 10,000 patient-years in long-term users 15

Effects That Trial Data Do Not Support

Back pain, joint pain, and fatigue appear at nearly identical rates in denosumab and placebo arms of FREEDOM 1. Patients who attribute these symptoms specifically to Prolia may be experiencing background osteoporosis-related pain or nocebo effects. A 2019 systematic review of nocebo effects in bisphosphonate and antiresorptive trials found that 20% to 35% of side-effect reports in active-drug arms could be attributed to expectation rather than pharmacology 16.

Rebound Fracture Risk After Stopping

This is the most clinically serious real-world concern, and it is validated by multiple observational studies. After denosumab is stopped, bone turnover markers rebound sharply within 3 to 6 months, often exceeding pre-treatment levels 8. Current AACE and Endocrine Society guidance recommends transitioning to zoledronic acid (5 mg IV) or an oral bisphosphonate within 6 months of the last denosumab injection to preserve BMD gains 4. A 2021 randomized trial (N=61) found that a single infusion of zoledronic acid given 6 months after the last Prolia shot maintained lumbar spine BMD within 1% of the denosumab-era level at 12 months 17.

Who Responds Best: Patient Characteristics Linked to Stronger Outcomes

Not every patient responds equally. Several baseline characteristics predict larger BMD gains and lower fracture rates.

Age and Baseline T-Score

Patients with lower baseline T-scores (more severe osteoporosis at treatment start) tend to show larger absolute BMD gains on denosumab, though the fracture-risk reduction is proportionally similar across severity strata 1. Younger postmenopausal women (ages 60 to 70) show slightly larger percentage BMD gains than women over 80, likely due to higher baseline bone turnover.

Vitamin D and Calcium Status

Adequate vitamin D (serum 25-OH-D above 30 ng/mL) and calcium intake (1,000 to 1,200 mg/day from diet plus supplements) are prerequisites for optimal denosumab response and reduce hypocalcemia risk 9. A 2018 analysis of the FREEDOM dataset found that patients with baseline 25-OH-D <20 ng/mL had a 3.1-fold higher risk of post-injection hypocalcemia than those with adequate levels 18.

Adherence to the 6-Month Schedule

The 6-month dosing interval is not flexible. Delaying an injection by more than 4 weeks allows bone turnover markers to rebound, partially eroding the antiresorptive effect. A pharmacokinetic analysis of denosumab dosing intervals found that a delay of 8 weeks beyond the scheduled injection date was associated with a 15% increase in bone resorption markers 19. Reddit discussions confirm that patients who miss injections due to insurance delays describe this experience with particular frustration, and several recount transient bone pain coinciding with the lapse.

Comparing User Sentiment Across Platforms

Different review platforms attract different patient profiles, which affects the apparent benefit-risk balance.

Platform-by-Platform Snapshot

| Platform | Approximate N | Mean Rating | Top Complaint | |---|---|---|---| | Drugs.com | ~350 | 6.2/10 | Injection-site pain, fatigue | | WebMD Reviews | ~180 | 6.5/10 | Joint pain, stopping anxiety | | r/Osteoporosis (Reddit) | ~400 posts | Qualitative only | Rebound fracture risk | | PatientsLikeMe | ~150 reporters | 62% "effective" | Fatigue, muscle weakness |

No platform constitutes a representative sample. Drugs.com and WebMD over-represent patients with side effects. Reddit over-represents patients who are engaged, anxious, or experienced a complication. PatientsLikeMe attracts patients with higher baseline health literacy and chronic-disease burden. These biases cannot be corrected without randomized survey design.

A 2021 analysis of online patient reviews for osteoporosis medications (N=2,412 reviews across three platforms) found that negative experiences generated 2.3 times more reviews per patient than positive experiences of equivalent magnitude 20.

Persistence and Long-Term Use: What Observational Data Show

Clinical trials measure outcomes in patients who adhere perfectly. Real-world persistence is lower and shapes population-level outcomes.

Persistence Rates

A 2019 retrospective cohort study using US insurance claims data (N=18,421 patients initiated on denosumab) found that 55.4% of patients remained on therapy at 24 months and 41.2% at 36 months 21. The primary reason for discontinuation was not side effects but insurance prior-authorization failure (cited in 34% of discontinuations). Cost concerns appeared in 18% of cases.

Impact of Persistence on Fracture Rates

A 2020 analysis of the FREEDOM Extension data stratified by injection timing found that patients who maintained the 6-month schedule with <4-week delays had a 23% lower incident fracture rate than those with recurrent delays 2. On-time dosing matters as much as the drug itself.

Practical Guidance for Current and Prospective Patients

Several concrete steps reduce the risk of the most common real-world problems with denosumab therapy.

Before Starting

Check serum 25-OH-D and correct deficiency to above 30 ng/mL before the first injection. Confirm eGFR; denosumab can be used at any eGFR but hypocalcemia risk rises as eGFR falls below 30 mL/min 5. Ensure a dental examination has been completed for patients with risk factors for ONJ (active periodontal disease, planned invasive dental work) 7.

During Therapy

Schedule injections every 6 months on a fixed calendar date. If insurance delays arise, escalate immediately, because a lapse beyond 7 months can trigger a measurable rebound in bone turnover markers 19. Arrange a DEXA scan at 12 to 24 months to confirm response; a gain of less than 3% in lumbar spine BMD at 24 months warrants reassessment of adherence and secondary causes of bone loss 4.

When Stopping

Never stop denosumab without a documented transition plan. The Endocrine Society recommends zoledronic acid 5 mg IV or oral alendronate 70 mg weekly starting within 6 months of the last injection 17. Patients who read Reddit accounts of rebound fractures and then stop Prolia out of fear, without seeking a bridging strategy, are substituting one risk for a worse one.